Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that bicalutamide mesotherapy resulted in subtle hair density improvements and was well tolerated by premenopausal women with androgenetic alopecia.

This study found that albumin-bound paclitaxel combined with nedaplatin shows promise as neoadjuvant therapy for esophageal squamous cell carcinoma, achieving a high complete response rate with manageable side effects.

In this study, researchers aimed to evaluate the safety and tolerability of low-dose oral minoxidil in adolescents, as existing data on its use in this population are limited and there are no specific pediatric guidelines for prescribing it. Results are not reported.

This study found that escalating baricitinib to 6 mg daily improved hair loss in 75% of patients with severe refractory alopecia areata who responded poorly to standard treatments, while also noting manageable short-term safety concerns under close monitoring.

This study observed that JAK inhibitors were safe and effective for patients with moderate-to-severe alopecia areata and comorbid latent hepatitis B or stable tuberculosis, with careful monitoring and selective prophylaxis.

This study found that midazolam, unlike clonazepam, increased neurosteroid levels and affected synaptic inhibition and plasticity in rat hippocampal neurons, suggesting unique actions via dual receptor activation.

This case report documents a 59-year-old woman who developed atypical drug-induced lupus after receiving infliximab for Crohn's disease, with symptoms persisting even after discontinuation.

This review concluded that JAK inhibitors are effective in achieving meaningful hair regrowth in moderate to severe alopecia areata, although continuous therapy is often needed to maintain the benefits.

Raltegravir may cause hair loss in some patients.

This study observed that oclacitinib, combined with oral glucocorticoids, achieved rapid and lasting clinical remission in four dogs with refractory juvenile-onset ischaemic dermatopathy, suggesting oclacitinib's potential as a useful immunosuppressive treatment in such cases.

This case series reported that low-dose naltrexone may benefit patients with lichen planopilaris by reducing scalp symptoms and slowing disease progression, with no adverse effects observed in the patients.

This case report describes a rare occurrence of giant bilateral adrenal myelolipomas in a 28-year-old female with CAH, emphasizing that large, hormonally active, or painful myelolipomas should be surgically removed.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

This study suggests that nail loss may be a new, reversible adverse event related to teriflunomide treatment, akin to its known effects on hair loss.

This case report describes how anifrolumab, used beyond trial-eligible populations, led to significant clinical and serological recovery in a 45-year-old woman with organ-threatening systemic lupus erythematosus complicated by infection and resistant to conventional treatments like cyclophosphamide and rituximab.

This study describes a case where immunochemotherapy, including chlorambucil and rituximab, successfully reversed agranulocytosis and other Waldenström's macroglobulinemia symptoms, indicating a possible connection between the two.

This report describes a case in which the use of the beta-blocker nadolol was associated with infiltrative dermatitis and significant alopecia, which resolved and resulted in total hair regrowth after discontinuation of the drug.

This study analyzed post-marketing data from the U.S. FDA Adverse Event Reporting System and identified both known and new safety concerns for Avacopan, an anti-neutrophil cytoplasmic antibodies-associated vasculitis treatment, emphasizing the need for monitoring during early treatment stages.

In this case study, a 39-year-old Japanese woman with severe alopecia areata demonstrated complete hair regrowth after one year using a combination of 0.5% delgocitinib ointment and excimer laser, suggesting potential efficacy and safety compared to conventional treatments.

This study reported that intensive immunosuppression in multiple sclerosis patients significantly reduced relapse rates versus pre-treatment expectations, though some required ongoing treatment after tapering.

In this case study, a 65-year-old male with hepatocellular carcinoma treated with the PD-1 inhibitor Sintilimab developed alopecia universalis alongside significant tumor regression and complete remission, highlighting a rare immune-related adverse event with effective anti-tumor outcomes.

This study demonstrated that de novo designed bifunctional proteins can target and degrade BCL-xL, leading to cell apoptosis, suggesting a new approach to targeted protein degradation therapy.

In this mouse study, applying a vasoconstrictor before chemotherapy did not create a leukemia sanctuary or significantly impact survival outcomes, suggesting it may not interfere with leukemia treatment.

This review describes the unique pharmacological profile and clinical applications of pegylated liposomal doxorubicin, emphasizing its role in Kaposi's sarcoma and recurrent ovarian cancer, but reports no new clinical results.

This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.

In this study, a risk score was developed and validated to identify patients at high risk of clinical failure after femoropopliteal peripheral vascular intervention, aiming to guide the selection of patients who may benefit from paclitaxel-coated devices or alternative strategies.

This study suggests that oral budesonide may not effectively maintain remission in Crohn's disease beyond three months, with minor benefits that are outweighed by increased rates of treatment-related adverse events.

This case report describes a 57-year-old man's late diagnosis of X-linked adrenoleukodystrophy, highlighting the need to consider this condition in patients with non-autoimmune primary adrenal insufficiency and neurological issues.